NJ Hospital First in the World to Use AI-Powered System to Treat Prostate Enlargement

On Sep 18, 2024

Earlier this month, Hackensack Meridian Hackensack University Medical Center became the first hospital in the world to treat patients with Aquablation® therapy using the new HYDROS™ Robotic System. This next-generation platform treats men suffering from benign prostatic hyperplasia (BPH), commonly known as an enlarged prostate.

Aquablation therapy is an innovative approach – delivering a heat-free waterjet so intense – that removes excess prostate tissue. The new HYDROS System is now delivered by an AI-powered robot that is clinically proven to provide significant, durable BPH symptom relief while preserving sexual function and continence across prostates of all shapes and sizes – a combination of benefits previously unattainable with traditional treatments.

BPH is a common consequence of aging, affecting half of all men between the ages of 51 and 60, with as many as 99% reporting a decrease in their quality of life. BPH impairs urinary function, making it considerably more difficult to urinate. Common symptoms include a weak urinary stream, a frequent or urgent need to urinate, nighttime urination, and trouble fully emptying the bladder. If left untreated, BPH can lead to serious health problems such as urinary tract infections, bladder stones, incontinence, retention of urine, and permanent bladder or kidney damage. When medications prove ineffective or cause troublesome side effects, surgery is often the standard treatment option; however, many surgical procedures can negatively affect sexual function and continence.

“The symptoms of BPH are very annoying,” described Abdo Saad who was recently diagnosed with the condition and not satisfied with traditional treatment options including medications or surgery. “I did my research to find a more innovative alternative,” explained the 66-year-old computer engineer, who was once named ‘Innovator of the Year’ by his own industry. “I knew there had to be something more state-of-the-art, which I found at Hackensack University Medical Center.” Mr. Saad sought the expertise of another innovator, Ravi Munver, MD, FACS, vice chair, Department of Urology and director of Minimally Invasive & Robotic Urologic Surgery at Hackensack University Medical Center. Dr. Munver explained the procedure, the advantages of the new technology, and receiving it from one of the Top 50 nationally ranked Urology (#17) programs in the country according to U.S. News & World Report’s 2024-25 Best Hospitals list. Mr. Saad was excited to be the first patient in the world to benefit from this cutting-edge advancement.

Aquablation therapy was designed to offer a minimally invasive and effective solution for BPH, minimizing the need for men to choose between safety and efficacy. Aquablation therapy is unique in its use of real-time, ultrasound-guided, robotic-assisted waterjet technology, allowing surgeons to create a personalized treatment plan that precisely targets which prostate tissue to remove and which to preserve. With this tailored approach, the system accurately removes problematic tissue while safeguarding critical anatomy.

The HYDROS Robotic System represents the next evolution in Aquablation therapy. It features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. It integrates next-generation ultrasound imaging and digital cystoscopy, providing surgeons with a multi-dimensional, detailed view of the entire prostate. The HYDROS System is designed to improve efficiency, enhance surgeon and staff experience, and deliver more accurate and consistent treatment plans for better clinical outcomes.

“We are thrilled to be at the forefront of this groundbreaking treatment,” said Robert C. Garrett, CEO, Hackensack Meridian Health. “Enlarged prostate affects millions of men worldwide, and this new procedure offers them a new hope for improved quality of life.”

To access more business news, visit NJB News Now.

Related Articles: